» Articles » PMID: 19589101

Heterophile Antibodies May Falsely Increase or Decrease Thyroglobulin Measurement in Patients with Differentiated Thyroid Carcinoma

Overview
Specialties Biochemistry
Pathology
Date 2009 Jul 11
PMID 19589101
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To examine the prevalence of significant interference from heterophile antibodies (HAb) in the measurement of serum thyroglobulin (Tg), we evaluated a large cohort of samples from patients with differentiated thyroid carcinoma (DTC).

Methods: Serum Tg measurements were performed in 406 serum samples before and after incubation of each serum sample in heterophile-blocking tubes (HBT) at room temperature for 1 h. We calculated the difference between the original Tg value and the value obtained after HBT treatment. We considered any sample showing an absolute percent difference >3 SD from the mean percent difference as being affected by HAb interference.

Results: We identified five patients (1%) as showing interference from HAb. Of these, three (60%) showed a false positive or falsely increased Tg concentration without any recurrence following clinical work-up; two (40%) showed a false negative or falsely reduced Tg levels, and metastases were detected in both cases by imaging procedures.

Conclusions: HAb may increase as well as reduce the measured Tg in a significant number of patients. A positive HAb interference should be suspected if Tg elevation does not fit the clinical pictures. A negative interference is a more challenging problem because increases in Tg generally occur as the first sign of recurrence of DTC. Therefore, treatment using HBT tubes of all sera referred for Tg measurement should be considered in order to prevent both unwarranted investigations or therapy, and delayed diagnosis of recurrence in patients affected by DTC.

Citing Articles

Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer.

Giovanella L, DAurizio F, Petranovic Ovcaricek P, Gorges R J Clin Med. 2024; 13(9).

PMID: 38730992 PMC: 11084486. DOI: 10.3390/jcm13092463.


False diagnosis of recurrent thyroid carcinoma: the importance of testing for heterophile antibodies.

Guastapaglia L, Chiamolera M, Lima Junior J, Ferrer C, Godoy Viana L, Veiga Chang C Arch Endocrinol Metab. 2024; 68:e230115.

PMID: 38456952 PMC: 11081039. DOI: 10.20945/2359-4292-2023-0115.


Thyroglobulin Assay Interferences: Clinical Usefulness of Mass-Spectrometry Methods.

Barbesino G, Algeciras-Schimnich A, Bornhorst J J Endocr Soc. 2022; 7(1):bvac169.

PMID: 36438548 PMC: 9683495. DOI: 10.1210/jendso/bvac169.


The role of Tg kinetics in predicting 2-[F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan.

Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Bertagna F, Giubbini R Endocrine. 2021; 74(2):332-339.

PMID: 34014437 PMC: 8497300. DOI: 10.1007/s12020-021-02755-5.


Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: a retrospective study.

Ora M, Nazar A, Mishra P, Barai S, Arya A, Pradhan P Thyroid Res. 2021; 14(1):8.

PMID: 33858456 PMC: 8048259. DOI: 10.1186/s13044-021-00099-w.